2-(4-morpholinyl)ethyl butanamide

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-(4-morpholinyl)ethyl butanamide
• 英文别名: N-(2-morpholino-ethyl)-butyramide；N-(2-Morpholino-aethyl)-butyramid；N-(2-morpholin-4-ylethyl)butanamide
• 化学式: C₁₀H₂₀N₂O₂
• mdl: MFCD03367788
• 分子量: 200.281
• InChiKey: DENKEFCOKVMHQJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  N-(2-氨基乙基)吗啉 、 丁酸乙酯 生成 2-(4-morpholinyl)ethyl butanamide
  参考文献：
  名称：

  N-(β-Aminoethyl)-morpholine as a Reagent for the Characterization of Esters

  摘要：

  DOI：

  10.1021/ja01149a018

文献信息

• Imidazolothiazole compounds for the treatment of disease
  申请人：Bhagwat Shripad

  公开号：US20070232604A1

  公开（公告）日：2007-10-04

  Compounds, compositions and methods are provided for modulating the activity of receptor kinases and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by receptor kinases.

  提供了用于调节受体激酶活性以及用于治疗、预防或改善由受体激酶介导的一种或多种疾病或紊乱症状的化合物、组合物和方法。
• [EN] DERIVATIVES OF BUTYRIC ACID AND USES THEREOF<br/>[FR] DERIVES D'ACIDE BUTYRIQUE ET SES UTILISATIONS
  申请人：UNIV ARKANSAS

  公开号：WO2000073257A1

  公开（公告）日：2000-12-07

  The present invention provides a series of compounds having structural formulas (I), (II), (III), (IV) wherein n1 is 1 to 5, n2 is 1 to 4 and m is 1 to 3; X is O or NH; Y is CH2, O, S, NH, NR; R is selected from the group consisting a straight-chain aliphatic group, a branched-chain aliphatic group and an alicyclic group; wherein R' is selected from the group consisting of hydrogen, methyl and ethyl; when Y is O, n1 is not 1; and wherein X and R' are independently optionally substituted at C2, C3 or C4 in compounds of Formula (IV) or a pharmaceutically acceptable salt thereof. Also provided is a method of inactivating antigen-specific T cells in an individual.

  本发明提供了一系列具有结构式（I）、（II）、（III）、（IV）的化合物，其中n1为1至5，n2为1至4，m为1至3；X为O或NH；Y为CH2、O、S、NH、NR；R选自直链脂肪基、支链脂肪基和脂环族基；其中R'选自氢、甲基和乙基；当Y为O时，n1不为1；在化合物（IV）或其药学上可接受的盐中，X和R'在C2、C3或C4上可独立地选用可选的取代基。本发明还提供了一种在个体中失活抗原特异性T细胞的方法。
• Derivatives of butyric acid and uses thereof
  申请人：The University of Arkansas for Medical Sciences

  公开号：US20040127564A1

  公开（公告）日：2004-07-01

  The present invention provides a series of compounds having structural formulas 1 wherein n 1 is 1 to 5, n 2 is 1 to 4 and m is 1 to 3; X is 0 or NH; Y is CH2, O, S, NH, NR; R is selected from the group consisting a straight-chain aliphatic group, a branched-chain aliphatic group and an alicyclic group; wherein R′ is selected from the group consisting of hydrogen, methyl and ethyl; when Y is O, n 1 is not 1; and wherein X and R′ are independently optionally substituted at C2, C3 or C4 in compounds of Fomula IV or a pharmaceutically acceptable salt thereof. Also provided is a method of inactivating antigen-specific T cells in a n individual.

  本发明提供了一系列化合物，其结构式为1，其中n1为1至5，n2为1至4，m为1至3；X为0或NH；Y为CH2、O、S、NH、NR；R选自直链脂肪族基团、支链脂肪族基团和脂环族基团；其中R'选自氢、甲基和乙基；当Y为O时，n1不为1；且在公式IV的化合物或其药学上可接受的盐中，X和R'在C2、C3或C4上独立地可选地被取代。还提供了一种在个体中灭活抗原特异性T细胞的方法。
• CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
  申请人：Wityak John

  公开号：US20110230428A1

  公开（公告）日：2011-09-22

  Certain chemical entities are provided herein. Pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

  本文提供了某些化学实体。其中包括至少一种化学实体和一个或多个药学可接受载体的制药组合物。本文还描述了治疗对KMO活性抑制有反应的某些疾病和疾病的方法，包括向这些患者施用至少一种化学实体的数量，以减少疾病或障碍的迹象或症状。这些疾病包括神经退行性疾病，如亨廷顿病。治疗方法包括将至少一种化学实体作为单个活性剂进行施用，或将至少一种化学实体与一个或多个其他治疗剂进行联合施用。此外，还提供了筛选能够抑制KMO活性的化合物的方法。
• METHOD OF USING IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE
  申请人：Bhagwat Shripad

  公开号：US20100298313A1

  公开（公告）日：2010-11-25

  Compounds, compositions and methods are provided for modulating the activity of receptor kinases and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by receptor kinases.

  本发明提供了化合物、组合物和方法，用于调节受体激酶的活性，并用于治疗、预防或改善由受体激酶介导的一种或多种疾病或障碍的症状。